Roberto J. Groszmann

Roberto J. Groszmann's AcademicInfluence.com Rankings

Philosophy

#6497

World Rank

#9542

Historical Rank

Logic

#3652

World Rank

#4844

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Roberto J. Groszmann's Degrees

Doctorate Medicine University of California, San Francisco
PhD Biomedical Sciences University of California, San Francisco

Why Is Roberto J. Groszmann Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Roberto J. Groszmann's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Portal pressure, presence of gastroesophageal varices and variceal bleeding (1985) (889)
Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. (2005) (881)
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. (2007) (865)
Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. (1990) (577)
The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule (2006) (515)
The hepatic venous pressure gradient: Anything worth doing should be done right (2004) (462)
The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enough (2002) (443)
Portal hypertension and variceal bleeding: An AASLD single topic symposium (1998) (421)
Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. (1983) (404)
Hyperdynamic circulation of liver disease 40 years later: Pathophysiology and clinical consequences (1994) (376)
Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats (1998) (363)
Current management of portal hypertension. (2003) (354)
Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. (1999) (338)
Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. (2009) (328)
Increased blood flow through the portal system in cirrhotic rats. (1984) (322)
Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. (1997) (316)
Short‐term effects of propranolol on portal venous pressure (1986) (295)
Vascular endothelial dysfunction in cirrhosis. (2007) (293)
Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. (1999) (291)
Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. (1996) (290)
Role of Nitric Oxide (1998) (268)
Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. (1985) (260)
Measurement of portal-systemic shunting in the rat by using gamma-labeled microspheres. (1981) (252)
Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. (2003) (245)
Portal hypertension and variceal bleeding—Unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single‐topic conference (2008) (244)
Nitric oxide synthase generates nitric oxide locally to regulate compartmentalized protein S-nitrosylation and protein trafficking (2006) (238)
Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. (2006) (232)
Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension (1982) (226)
Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. (1993) (213)
Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis (2011) (213)
Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. (2009) (212)
Tumor necrosis factor α: A major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats (1995) (206)
Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. (1992) (202)
Measurement of Azygos Venous Blood Flow by a Continuous Thermal Dilution Technique: An Index of Blood Flow Through Gastroesophageal Collaterals in Cirrhosis (1984) (199)
Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial (1991) (190)
Increased portal venous resistance hinders portal pressure reduction during the administration of β‐adrenergic blocking agents in a portal hypertensive model (1985) (184)
Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. (2006) (182)
Nitric oxide modulates hepatic vascular tone in normal rat liver. (1994) (181)
Portal Hypertension in Children: Expert Pediatric Opinion on the Report of the Baveno V Consensus Workshop on Methodology of Diagnosis and Therapy in Portal Hypertension (2012) (181)
Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. (1999) (178)
Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments. (2015) (177)
Splanchnic and systemic hemodynamics in portal hypertensive rats during hemorrhage and blood volume restitution. (1986) (170)
Observer variability in echo-Doppler measurements of portal flow in cirrhotic patients and normal volunteers. (1990) (162)
The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats (1992) (159)
Wedged and free hepatic venous pressure measured with a balloon catheter (1978) (150)
Hsp90 regulation of endothelial nitric oxide synthase contributes to vascular control in portal hypertension. (1999) (150)
Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portal‐hypertensive rats (1992) (148)
Thalidomide inhibits tumor necrosis factor α, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal‐hypertensive rats (1996) (146)
Administration of Nω-nitro-l-arginine ameliorates portal-systemic shunting in portal-hypertensive rats (1993) (142)
Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis (2007) (132)
Enhanced release of nitric oxide in response to changes in flow and shear stress in the superior mesenteric arteries of portal hypertensive rats (1998) (129)
Portal hypertension: from bedside to bench. (2005) (126)
Propranolol for the prevention of first esophageal variceal hemorrhage: A lifetime commitment? (2001) (123)
Pathophysiology of portal hypertension. (1997) (121)
Quantitation of portasystemic shunting from the splenic and mesenteric beds in alcoholic liver disease. (1972) (120)
Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point? (2002) (119)
Wedged and free hepatic venous pressure measured with a balloon catheter. (1979) (119)
Vasodilatation and sodium retention in prehepatic portal hypertension. (1992) (119)
Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. (1997) (118)
Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis (1999) (118)
In vitro hyporeactivity to methoxamine in portal hypertensive rats: reversal by nitric oxide blockade. (1992) (115)
II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. (2003) (115)
NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. (1999) (110)
Evaluation of postprandial hyperemia in superior mesenteric artery and portal vein in healthy and cirrhotic humans: An operator‐blind echo‐Doppler study (1991) (108)
Nω‐Nitro‐L‐arginine Administration Corrects Peripheral Vasodilation and Systemic Capillary Hypotension and Ameliorates Plasma Volume Expansion and Sodium Retention in Portal Hypertensive Rats (1993) (107)
Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: A placebo‐controlled clinical trial (1989) (107)
Propranolol ameliorates the development of portal-systemic shunting in a chronic murine schistosomiasis model of portal hypertension. (1991) (106)
Primary prophylaxis of variceal bleeding in children and the role of MesoRex Bypass: Summary of the Baveno VI Pediatric Satellite Symposium (2016) (106)
Distal splenorenal vs. portal‐systemic shunts after hemorrhage from varices: A randomized controlled trial (1988) (104)
Bacterial translocation up‐regulates GTP‐cyclohydrolase I in mesenteric vasculature of cirrhotic rats (2003) (103)
A controlled comparison of continuous intraarterial and intravenous infusions of vasopressin in hemorrhage from esophageal varices (1979) (101)
Hepatic blood flow in alcoholic liver disease measured by an indicator dilution technic. (1972) (100)
Chronic Bile Duct Ligation in the Dog: Hemodynamic Characterization of a Portal Hypertensive Model (2007) (99)
Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats. (2001) (98)
Role of endothelium in the abnormal response of mesenteric vessels in rats with portal hypertension and liver cirrhosis. (1996) (91)
Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension. (2002) (90)
Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. (2002) (87)
Reassessing portal venous pressure measurements. (1984) (84)
Effect of selective blockade of beta 2-adrenergic receptors on portal and systemic hemodynamics in a portal hypertensive rat model. (1985) (84)
Adenosine induces loss of actin stress fibers and inhibits contraction in hepatic stellate cells via Rho inhibition (2009) (82)
Splanchnic hemodynamics in portal-hypertensive rats: measurement with gamma-labeled microspheres. (1982) (80)
The pathophysiology of portal hypertension: a basis for classification. (1982) (79)
Expert pediatric opinion on the Report of the Baveno IV Consensus Workshop on Methodology of Diagnosis and Therapy in Portal Hypertension (2006) (78)
Quantitative histological‐hemodynamic correlations in cirrhosis (2012) (77)
Interaction of flow and resistance in maintenance of portal hypertension in a rat model. (1986) (77)
Circulation times in the splanchnic and hepatic beds in alcoholic liver disease. (1972) (77)
A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats. (2003) (75)
Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. (2003) (75)
Long‐term hemodynamic effects of ketanserin, a 5‐hydroxytryptamine blocker, in portal hypertensive patients (1989) (75)
Effect of somatostatin on mesenteric vascular resistance in normal and portal hypertensive rats. (1992) (75)
Pharmacology of portal-systemic collaterals in portal hypertensive rats: role of endothelium. (1992) (74)
Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. (1995) (73)
Hyperdynamic state in chronic liver diseases. (1993) (71)
Transient elastography for diagnosis of portal hypertension in liver cirrhosis: Is there still a role for hepatic venous pressure gradient measurement? (2007) (71)
Local arterial vasoconstriction induced by octreotide in patients with cirrhosis (2000) (70)
Octreotide blunts postprandial splanchnic hyperemia in cirrhotic patients: A double‐blind randomized echo‐doppler study (1995) (70)
Portal hemodynamics during nitroglycerin administration in cirrhotic patients (1987) (70)
I. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease: effects on drinking behavior by nurse/physician teams. (2003) (67)
The hepatic circulation in health and disease: Report of a single‐topic symposium (1998) (66)
Hemodynamic evaluation of isosorbide dinitrate in alcoholic cirrhosis. Pharmacokinetic-hemodynamic interactions. (1987) (66)
The portal pressure response to beta-blockade is greater in cirrhotic patients without varices than in those with varices. (1997) (65)
The value of Doppler US in the study of hepatic hemodynamics. Consensus conference (Bologna, Italy, 12 September, 1989). (1990) (65)
Low‐dose midazolam sedation: An option for patients undergoing serial hepatic venous pressure measurements (1999) (63)
Octreotide ameliorates vasodilatation and Na+ retention in portal hypertensive rats. (1993) (61)
Child-Turcotte-Pugh Class is Best at Stratifying Risk in Variceal Hemorrhage: Analysis of a US Multicenter Prospective Study (2017) (60)
Deficit in nitric oxide production in cirrhotic rat livers is located in the sinusoidal and postsinusoidal areas. (2003) (58)
Beta-adrenergic blockers and nitrovasodilators for the treatment of portal hypertension: the good, the bad, the ugly. (1997) (58)
103 Multicenter randomized placebo-controlled trial of non-selective beta-blockers in the prevention of the complications of portal hypertension: final results and identification of a predictive factor (2003) (57)
Pathophysiology of portal hypertension and variceal bleeding. (1990) (56)
Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. (2020) (56)
The role of central blood volume in the development of sodium retention in portal hypertensive rats. (1996) (56)
Sequence of morphological and hemodynamic changes of gastric microvessels in portal hypertension. (1992) (56)
Bioactivation of nitroglycerin and vasomotor response to nitric oxide are impaired in cirrhotic rat livers (2002) (55)
Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients (2014) (55)
Reticulon 4B (Nogo‐B) is a novel regulator of hepatic fibrosis (2011) (54)
Splanchnic and systemic hemodynamics in mice using a radioactive microsphere technique. (1990) (54)
Intrahepatic arteriovenous shunting in cirrhosis of the liver. (1977) (48)
Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers. (2006) (46)
Effect of Lactobacillus-Fermented Diets on Bacterial Translocation and Intestinal Flora in Experimental Prehepatic Portal Hypertension (2003) (46)
Pharmacologic treatment of portal hypertension. (1992) (44)
A randomized study of propranolol on postprandial portal hyperemia in cirrhotic patients. (1992) (42)
Measurement of portal pressure: when, how, and why to do it. (2006) (41)
Adrenomedullin, a Vasodilator Peptide Implicated in Hemodynamic Alterations of Liver Cirrhosis Relationship to Nitric Oxide (1999) (41)
Endoscopic variceal banding vs. pharmacological therapy for the prevention of recurrent variceal hemorrhage: what makes the difference? (2002) (40)
Compensatory mechanisms in response to an elevated hepatic oxygen consumption in chronically ethanol-fed rats. (1985) (38)
Administration of N omega-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. (1993) (38)
Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure (2012) (37)
Feasibility spectrum for Doppler flowmetry of splanchnic vessels. In normal and cirrhotic populations. (1990) (36)
Hyposensitivity to vasopressin in a hemorrhaged-transfused rat model of portal hypertension. (1987) (36)
Sildenafil has no effect on portal pressure but lowers arterial pressure in patients with compensated cirrhosis. (2010) (35)
1 Pathophysiology of portal hypertension (1997) (34)
Blood in the gastric lumen increases splanchnic blood flow and portal pressure in portal-hypertensive rats. (1996) (34)
Cardiovascular hyporesponsiveness to norepinephrine, propranolol and nitroglycerin in portal‐hypertensive and aged rats (1993) (33)
The diagnostic and predictive value of ascites nitric oxide levels in patients with spontaneous bacterial peritonitis (1998) (31)
Diagnosing portal hypertension. (2000) (30)
NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. (1999) (30)
The Measurement of Liver Blood Flow Using Clearance Techniques (2007) (30)
Hemodynamic mechanisms of emerging portal hypertension caused by schistosomiasis in the hamster (1990) (29)
Gastric vascular changes in portal hypertension (1988) (28)
A controlled comparison of continuous intraarterial and intravenous infusions of vasopressin in hemorrhage from esophageal varices. (1979) (27)
Portal hypertension ameliorates arterial hypertension in spontaneously hypertensive rats. (1989) (27)
The hepatic venous pressure gradient: Has the time arrived for its application in clinical practice? (1996) (26)
Hepatic lobar distribution of splenic and mesenteric blood flow in man. (1971) (25)
ICI 169,369 selectively blocks 5-hydroxytryptamine2 receptors and lowers portal pressure in portal hypertensive rats. (1988) (24)
Decreased mesenteric vascular response to angiotensin II in portal hypertension. (1990) (24)
Portal pressure reduction induced by partial mechanical obstruction of the superior mesenteric artery in the anesthetized dog. (1978) (21)
Hyperdynamic circulation in a chronic murine schistosomiasis model of portal hypertension (1991) (20)
Vasoconstrictor therapy for the hepatorenal syndrome. (2008) (19)
Platelet cytosolic calcium, peripheral hemodynamics, and vasodilatory peptides in liver cirrhosis. (1993) (19)
The role of hepatic arterial flow on portal venous and hepatic venous wedged pressure in the isolated perfused CCl4-cirrhotic liver. (2008) (18)
Comparative Effect of Nitroglycerin and Nitroprusside on Vasopressin‐Induced Cardiac Dysfunction in the Dog (1983) (18)
Pharmacological treatment of portal hypertension. (1996) (18)
Increased neuronal nitric oxide synthase interaction with soluble guanylate cyclase contributes to the splanchnic arterial vasodilation in portal hypertensive rats (2007) (18)
Bile acids do not mediate the hyperdynamic circulation in portal hypertensive rats. (1990) (17)
Nitric oxide and vascular remodeling modulate hepatic arterial vascular resistance in the isolated perfused cirrhotic rat liver. (2008) (17)
Octreotide ameliorates the increase in collateral blood flow during postprandial hyperemia in portal hypertensive rats. (2002) (17)
Hepatic venous pressure gradient measurement in pre-primary and primary prophylaxis of variceal hemorrhage. (2013) (16)
Comparison of vasopressin and triglycyl-lysine vasopressin on splanchnic and systemic hemodynamics in dogs (1980) (16)
Glucagon and insulin metabolism in a portal-hypertensive rat model. (1987) (16)
Clinical Applications of the Measurement of Portal Venous Pressure (1980) (16)
Nitric Oxide and Hemodynamic Impairment (1998) (15)
Effect of Ethanol on Sulfobromophthalein and Indocyanine Green Metabolism in Isolated Perfused Rat Liver (1969) (15)
A distinct nitric oxide and adenosine A1 receptor dependent hepatic artery vasodilatatory response in the CCl4‐cirrhotic liver (2010) (15)
Catecholamines relax portal and mesenteric veins from normal and portal hypertensive rats. (1989) (13)
Spontaneous meningococcal peritonitis (1978) (12)
Prevalence , and Clinical Significance of Abnormal ematologic Indices in Compensated Cirrhosis (11)
N omega-nitro-L-arginine administration corrects peripheral vasodilation and systemic capillary hypotension and ameliorates plasma volume expansion and sodium retention in portal hypertensive rats. (1993) (11)
Effect of Sulfobromophthalein and Indocyanine Green on Bile Excretion (1969) (11)
Organic nitrates in portal hypertension. (1988) (11)
The pharmacologic treatment of portal hypertension. (1985) (11)
Resistance to reinfection in experimental murine schistosomiasis: role of porto-hepatic hemodynamics. (1989) (10)
LIVER, PANCREAS, AND BILIARY TRACT Tumor Necrosis Factor A Major Contributor to the Hyperdynamic Circulation in Prehepatic Portal-Hypertensive Rats (1995) (10)
Renal response to methoxamine in portal hypertensive rats: role of prostaglandins and nitric oxide. (1996) (10)
The interpretation of hepatic venous pressure gradient tracings – excellent interobserver agreement unrelated to experience (2016) (9)
The effect of hepatic arterial injection of contrast medium, blood, and saline on hepatic artery flow. (1978) (8)
Caveolin-1 in normal and cirrhotic human liver (2000) (7)
Idiopathic Portal Hypertension in a Renal Transplant Recipient (1982) (7)
Intrahepatic modulation of portal pressure and its role in portal hypertension. Role of nitric oxide. (1998) (7)
Study of indirect methods for measuring hepatic blood flow in the isolated perfused dog liver. (1975) (7)
Somatostatin in portal hypertension (1989) (6)
A reduction in the hepatic venous pressure gradient (HVPG) prevents clinical outcomes in compensated and decompensated cirrhosis: a meta-analysis (2017) (6)
Pharmacological vs. mechanical reduction in portal pressure: a comparative study. (1978) (6)
Buenos Aires to New Haven: A dream trip (2010) (5)
Intestinal O2 consumption during mechanical and pharmacological reduction in portal pressure. (1980) (5)
Different patterns of porta-systemic shunting in cirrhosis of the liver studied by an indicator dilution technique. (1971) (5)
Hemodynamic assessment in clinical practice in portal hypertensive cirrhotics (2001) (5)
Lack of hemodynamic response to long-acting octreotide (Sandostatin LAR) in patients with cirrhosis (2001) (4)
Pre-primary prophylaxis: can (and should) we prevent formation/growth of varices? (2001) (4)
Portal Hypertension—Molecular Mechanisms (2017) (3)
Hemodynamic studies in a parabiotic model of portal hypertension (1985) (3)
[Hyperdynamic circulatory syndrome of chronic liver disease: physiopathology of a multiorganic entity]. (1995) (3)
Increased splanchnic blood flow in portal hypertensive rats with cirrhosis and chronic portal vein ligation (1981) (2)
Hepatic oxygen consumption, in vivo, in the rat (1983) (2)
Hsp90 regulation of endothelial nitric oxide synthase contributes to vascular control in portal hypertension. (1999) (2)
Nitric oxide modulates both pre-sinusoidal and sinusoidal responses to phenylephrine in normal rat liver (2001) (2)
CLINICAL-LIVER, PANCREAS, AND BILIARY TRACT (2007) (2)
Hepatic venous pressure gradient: the facts (2004) (2)
Portal venous pressure measurement and its clinical significance. (1983) (2)
Drug Therapy for Acute Bleeding From Portal Hypertensive Gastropathy (1995) (2)
PTU-100 Efficacy of obeticholic acid treatment in patients with primary biliary cholangitis with cirrhosis (2017) (2)
Propranolol in the prophylaxis of oesophageal variceal haemorrhage in patients with cirrhosis: A double-blind, multicenter controlled trial (1990) (2)
Pathophysiology of portal hypertension. (1997) (1)
44 A liver-specific nitric oxide donor improves the intra-hepatic vascular response to increase portal blood flow and methoxamine in cirrhotic rats (2003) (1)
P013. Nitric oxide synthase establishes a local nitric oxide gradient regulating S-nitrosylation and protein secretion (2006) (1)
Introducing the AASLD president: Guadalupe Garcia‐Tsao (2012) (1)
Portal Hypertension in Alcoholic Cirrhosis (1989) (1)
Portal Hypertension/GI Bleeding (1998) (1)
Andres T. Blei, M.D. (October 19, 1949–October 1, 2008) (2009) (1)
553 Histologic-hemodynamic correlations in hepatitis C and other chronic liver diseases — is there a histologically mild and severe cirrhosis? (2003) (1)
The pharmacological therapy of portal hypertension. (1986) (1)
Pathogenesis of Portal Hypertension (2009) (1)
Nitric oxide is a mediator of the adenosine-induced vasodilatation of the hepatic artery in CCl4-cirrhotic rats (2007) (1)
238 The effect of hepatic arterial blood flow changes on portal and hepatic venous wedged pressure in the isolated perfused CCl4-cirrhotic liver (2006) (1)
Intraarterial vs intravenous vasopressin in the treatment of massive upper gastrointestinal hemorrhage (1978) (1)
[Effect of silymarin on carbon-tetrachloride- induced hepatotoxicity in rats]. (1976) (1)
Pre‐Primary and Primary Prophylaxis: What Should We Do Next? (2010) (1)
Imaging techniques and Haemodynamic Measurements in Portal Hypertension (1996) (1)
Comparative effects of triglycyl vasopressin and vasopressin infusion in dogs with portal hypertension (1978) (1)
[The pathophysiological basis of the pharmacological treatment of portal hypertension]. (1986) (1)
The phosphorylation of endothelial nitric oxide synthase by Akt increases nitric oxide production in early portal hypertension (2001) (1)
Primary Prophylaxis of First Variceal Bleeding (2016) (1)
Comparative effects of systemic and intraarterial vasopressin and partial balloon obstruction of the superior mesenteric artery upon intestinal oxygen consumption (1978) (0)
Impaired vasodilation in cirrhotic livers (2004) (0)
Consensus Statements: Changing Scenarios: Prevention of Decompensation (2016) (0)
HEMODYNAMIC IMPAIRMENT IN PORTAL HYPERTENSION (1998) (0)
Bacterial translocation to mesenteric lymph nodes impairs vascular contractility in superior mesenteric arteries of cirrhotic rats (1998) (0)
To the Editor (0)
Collateral hemodynamic changes during postprandial hyperemia in portal hypertensive rats (2000) (0)
Fever and hepatic blood flow. (1969) (0)
The role of central blood volume in the development of sodium retention in portal hypertensive rats (1996) (0)
S1918 A Hemodynamic Response to Treatment With Non-Selective Beta-Blockers Protects Against Worsening of Thrombocytopenia in Cirrhosis (2010) (0)
Impaired nitric oxide release in cirrhotic rat liver agauF.^Haddad (1998) (0)
9 vasodilation in cirrhotic livers (2004) (0)
The paradox: vasoconstriction and vasodilation (2004) (0)
Neuronal nitric oxide synthase(NNOS) is upregulated in superior mesenteric arteries in portal hypertensive rats (2003) (0)
To the Editor (0)
7.2. Pathogenesis of Portal Hypertension (2008) (0)
Portal Hypertension: Intrahepatic Mechanisms (2011) (0)
Correspondence. Liver Blood Flow Using Clearance Techniques (1984) (0)
Drug therapy of portal hypertension. (1987) (0)
門脈圧亢進症および静脈瘤出血--未解決の問題。米国肝臓学会および欧州肝臓学会共同主催のシングルトピックカンファレンスの概要 (2008) (0)
splanchnic circulation in portal hypertensive rats NO overproduction by eNOS precedes hyperdynamic (2016) (0)
Beta error vs. nonsignificant significance (1980) (0)
98. Portal hypertension (2012) (0)
Mesenteric vasoconstriction is responsible for the initial eNOS upregulation in the superior mesenteric artery of portal hypertensive rats (2003) (0)
[Editorial: Biliary lithiasis (author's transl)]. (1973) (0)
Pathophysiology of Bleeding and Hepatorenal Syndrome (1998) (0)
Ultrasound parameters in the prediction of clinically significant portal hypertension (CS-PHT) in compensated cirrhosis (2000) (0)
Physiology of Hepatic Circulation in Cirrhosis (2007) (0)
Choleresis Induced by Lithocholic Acid in the Rat (1976) (0)
[Endothelial factors in portal hypertension]. (1994) (0)
260 BETA-BLOCKERS MODULATE A PORTAL HYPOTENSIVE EFFECT OF HEPATIC ARTERIAL FLOW ON PORTAL PRESSURE THROUGH BETA-2 ADRENOCEPTORS (2008) (0)
Octreotide potentiates local vasoconstriction in superior mesenteric arteries: Mechanism and pharmacodynamics in portal hypertensive and control rats (2000) (0)
Arterial vasodilatation precedes sodium retention in prehepatic portal hypertension (1991) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Roberto J. Groszmann?

Roberto J. Groszmann is affiliated with the following schools:

Yale University